血清ProGRP在小细胞肺癌诊疗中的应用

Application of serum levels of Pro GRP in the diagnosis and treatment of small cell lung carcinomas

目的 探讨血清胃泌素释放肽前体（Pro GRP）在小细胞肺癌诊疗中的临床应用价值。方法 纳入来我院就诊、体检的431例患者为研究对象,分组情况为小细胞肺癌组65例;其他肺癌组227例;其他肿瘤组63例;对照组76例。检测四组患者的血清Pro GRP含量。结果 小细胞肺癌组与其他三组的血清pro GRP结果比较,差异有统计学意义（χ~2=87.92,P=0.000）,其他三组结果差异无统计学意义（P〉0.05）。20例小细胞肺癌放化疗前后1个月后的血清pro GRP结果比较,差异有统计学意义（Z=-2.803,P=0.005）。结论 血清Pro GRP在小细胞肺癌的早期诊断、鉴别诊断以及治疗监测方面发挥重要作用。

Objective To explore the clinical application of serum gastrin releasing peptide precursor （ProGRP） in the diagnosis and treatment of small cell lung cancer. Methods Four hundred and thirty-one individuals who were treated or accepted physical examination in our hospital were selected, and in which 65 cases were classified to small cell lung cancer group, 227 cases were classified to other lung cancer group, 63 cases were classified to other tumor group, and 76 cases were classified to control group. Serum ProGRP levels were measured in four the groups. Results The difference of serum ProGRP levels in small cell lung cancer group and the other three groups was statistically significant （XZ=87.92, P=0.000）, and there was no significant difference among the other three groups （P 〉0.05）. The difference of serum ProGRP levels in 20 cases of small cell lung cancer patients before and 1 month after the radiotherapy and chemotherapy was statistically significant （Z=-2.803,P=0.005）. Conclusion Serum ProGRP plays an important role in the early diagnosis, differential diagnosis and treatment monitoring of small cell lung cancer.